@article{ART002885411,
author={Lei Miao and Jing Xu and Giovanni Targher and Christopher D Byrne and Ming-Hua Zheng},
title={Old and new classes of glucose-lowering agents as treatments for non-alcoholic fatty liver disease: A narrative review},
journal={Clinical and Molecular Hepatology},
issn={2287-2728},
year={2022},
volume={28},
number={4},
pages={725-738}
}

TY - JOUR
AU - Lei Miao
AU - Jing Xu
AU - Giovanni Targher
AU - Christopher D Byrne
AU - Ming-Hua Zheng
TI - Old and new classes of glucose-lowering agents as treatments for non-alcoholic fatty liver disease: A narrative review
T2 - Clinical and Molecular Hepatology
JO - Clinical and Molecular Hepatology
PY - 2022
VL - 28
IS - 4
PB - 대한간학회
SP - 725
EP - 738
SN - 2287-2728
AB - Non-alcoholic fatty liver disease (NAFLD) has become the most common chronic liver disease with a global prevalence of about 55% in people with type 2 diabetes mellitus (T2DM). T2DM, obesity and NAFLD are three closely inter-related pathological conditions. In addition, T2DM is one of the strongest clinical risk factors for the faster progression of NAFLD to non-alcoholic steatohepatitis (NASH), cirrhosis and hepatocellular carcinoma. Increasing evidence suggests that newer classes of glucose-lowering drugs, such as peroxisome proliferator-activated receptor agonists, glucagon-like peptide-1 receptor agonists, dipeptidyl peptidase-4 inhibitors or sodium-glucose cotransporter-2 inhibitors, could reduce the rates of NAFLD progression. This narrative review aims to briefly summarize the recent results from randomized controlled trials testing the efficacy and safety of old and new glucose-lowering drugs for the treatment of NAFLD or NASH in adults both with and without coexisting T2DM.
KW - Non-alcoholic fatty liver disease, Type 2 diabetes mellitus, Glucose-lowering drugs, Metabolic dysfunctionassociated fatty liver disease
DO -
UR -
ER -

Lei Miao, Jing Xu, Giovanni Targher, Christopher D Byrne and Ming-Hua Zheng. 2022, "Old and new classes of glucose-lowering agents as treatments for non-alcoholic fatty liver disease: A narrative review", Clinical and Molecular Hepatology, vol.28, no.4 pp.725-738.

Lei Miao, Jing Xu, Giovanni Targher, Christopher D Byrne, Ming-Hua Zheng "Old and new classes of glucose-lowering agents as treatments for non-alcoholic fatty liver disease: A narrative review" Clinical and Molecular Hepatology 28.4 pp.725-738 (2022) : 725.

Lei Miao, Jing Xu, Giovanni Targher, Christopher D Byrne, Ming-Hua Zheng. Old and new classes of glucose-lowering agents as treatments for non-alcoholic fatty liver disease: A narrative review. 2022; 28(4), 725-738.

Lei Miao, Jing Xu, Giovanni Targher, Christopher D Byrne and Ming-Hua Zheng. "Old and new classes of glucose-lowering agents as treatments for non-alcoholic fatty liver disease: A narrative review" Clinical and Molecular Hepatology 28, no.4 (2022) : 725-738.

Lei Miao; Jing Xu; Giovanni Targher; Christopher D Byrne; Ming-Hua Zheng. Old and new classes of glucose-lowering agents as treatments for non-alcoholic fatty liver disease: A narrative review. Clinical and Molecular Hepatology, 28(4), 725-738.

Lei Miao; Jing Xu; Giovanni Targher; Christopher D Byrne; Ming-Hua Zheng. Old and new classes of glucose-lowering agents as treatments for non-alcoholic fatty liver disease: A narrative review. Clinical and Molecular Hepatology. 2022; 28(4) 725-738.

Lei Miao, Jing Xu, Giovanni Targher, Christopher D Byrne, Ming-Hua Zheng. Old and new classes of glucose-lowering agents as treatments for non-alcoholic fatty liver disease: A narrative review. 2022; 28(4), 725-738.

Lei Miao, Jing Xu, Giovanni Targher, Christopher D Byrne and Ming-Hua Zheng. "Old and new classes of glucose-lowering agents as treatments for non-alcoholic fatty liver disease: A narrative review" Clinical and Molecular Hepatology 28, no.4 (2022) : 725-738.